FDA approves ABRAXANE chemotherapy drug for treatment of metastatic pancreatic cancer
The Pancreatic Cancer Action Network is pleased to announce that today ABRAXANE® was approved by the U.S. Food and Drug Administration (FDA) to treat metastatic pancreatic cancer.